Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET

Company Participants

Andrew McKibben - Vice President, Investor Relations
Chris Peetz - Chief Executive Officer
Peter Radovich - President & Chief Operating Officer
Joanne Quan - Chief Medical Officer
Eric Bjerkholt - Chief Financial Officer

Conference Call Participants

Jessica Fye - JPMorgan
Mani Foroohar - Leerink Partners
Gavin Clark-Gartner - Evercore ISI
Dae Gon Ha - Stifel
Steven Seedhouse - Raymond James
David Lebowitz - Citi
Jon Wolleben - Citizens JMP
Thomas Yip - H.C. Wainwright

Operator

Hello, and welcome to the Mirum Pharmaceuticals First Quarter 2024 Financial Results and Business Update. My name is Terry, and I will be the conference operator today. All lines have been placed on mute to prevent any background noise. [Operator Instructions]

I will now hand the call over to Andrew McKibben, Vice President of Investor Relations, to begin. Please go ahead.

Andrew McKibben

Thanks, Terry, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals first quarter 2024 conference call.

I'm joined today by our CEO, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; Chief Medical Officer, Joanne Quan; and Eric Bjerkholt, our Chief Financial Officer.

Earlier today, Mirum issued a news release announcing the company's results for the first quarter 2024. Copies of this news release and SEC filings can be found in the Investors section of our website.

Before we begin, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements about Mirum and our programs based on management's current expectations, including statements regarding Mirum's current and future business plans, development programs and regulatory expectations, strategies, prospects, market opportunities and financial expectations. Mirum is under no duty to update these statements, and they are subject to numerous risks and uncertainties, and actual results could differ materially from the results anticipated by these statements. Investors should read the risk factors set forth in Mirum's 10-Q for the quarter ended March 31, 2024, and any subsequent reports filed with the SEC.

With that said, I'd like to turn the call over to Chris. Chris?

Chris Peetz

Thanks, Andrew, and good afternoon to everyone.

2024 is tracking to be another year of significant growth for us. And I'm very pleased to highlight our progress across key strategic objectives to grow the commercial business, expand the indications of our commercial medicines and advanced volixibat to market. We continue to build value while delivering on our commitment to create and commercialize life-changing medicines for rare disease.